Edwards Lifesciences Corp [EW] Stock trading around $72.54 per share: What’s Next?

Edwards Lifesciences Corp [NYSE: EW] loss -3.06% or -2.29 points to close at $72.54 with a heavy trading volume of 4438754 shares. The company report on January 2, 2024 at 9:00 AM that Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference.

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day.

The daily chart for EW points out that the company has recorded -20.88% loss over the past six months.

If we look at the average trading volume of 4.54M shares, EW reached to a volume of 4438754 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Edwards Lifesciences Corp [EW]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EW shares is $79.37 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EW stock is a recommendation set at 2.16. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Evercore ISI have made an estimate for Edwards Lifesciences Corp shares, keeping their opinion on the stock as In-line, with their previous recommendation back on January 04, 2024.

The Average True Range (ATR) for Edwards Lifesciences Corp is set at 1.76, with the Price to Sales ratio for EW stock in the period of the last 12 months amounting to 7.56. The Price to Book ratio for the last quarter was 6.61, with the Price to Cash per share for the same quarter was set at 3.07. Price to Free Cash Flow for EW in the course of the last twelve months was 54.42 with Quick ratio for the last quarter at 2.45.

Trading performance analysis for EW stock

Edwards Lifesciences Corp [EW] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.73. With this latest performance, EW shares dropped by -3.22% in over the last four-week period, additionally sinking by -20.88% over the last 6 months – not to mention a drop of -9.39% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EW stock in for the last two-week period is set at 43.96, with the RSI for the last a single of trading hit 37.00, and the three-weeks RSI is set at 47.69 for Edwards Lifesciences Corp [EW]. The present Moving Average for the last 50 days of trading for this stock 71.83, while it was recorded at 74.26 for the last single week of trading, and 78.47 for the last 200 days.

Edwards Lifesciences Corp [EW]: A deeper dive into fundamental analysis

Edwards Lifesciences Corp’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.45 and a Current Ratio set at 3.28.

Edwards Lifesciences Corp [EW]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Edwards Lifesciences Corp posted 0.64/share EPS, while the average EPS was predicted by analysts to be reported at 0.61/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EW. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Edwards Lifesciences Corp go to 7.99%.

An analysis of Institutional ownership at Edwards Lifesciences Corp [EW]

The top three institutional holders of EW stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in EW stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in EW stock with ownership which is approximately 5.8325%.